Blogs

In the fast-paced world of drug discovery, every day counts—and so does every drop of solvent. Yet for chemists working with polar, unstable prodrugs and new chemical entities (NCEs), one critical step has remained frustratingly slow, expensive, and inefficient: purification.

In today’s rapidly evolving world, a resilient supply chain is no longer optional for the biopharma industry; it’s a strategic necessity.

Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions.

Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras).

As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.

Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.

A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.

The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.

Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.

Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.